Related Experiment Video
Updated: Jun 25, 2025
In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
Targeting BMP2 for therapeutic strategies against hepatocellular carcinoma
Ping Li1, You Shang2, Liying Yuan2
1Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, PR China.
Objectives:
This study aimed to investigate the role of BMP2 in hepatocellular carcinoma (HCC) growth and metastasis using a dual approach combining single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq.
Methods:
scRNA-seq data from the GEO database and bulk RNA-seq data from the TCGA database were analyzed. Differentially expressed marker genes of endothelial cells were identified and analyzed using enrichment analysis, PPI analysis, correlation analysis, and GSEA. In vitro, experiments were conducted using the Huh-7 HCC cell line, and in vivo, models of HCC growth and metastasis were established by knocking down BMP2.
Results:
The scRNA-seq analysis identified BMP2 as a key marker gene in endothelial cells of HCC samples. Elevated BMP2 expression correlated with poor prognosis in HCC. In vitro experiments showed that silencing BMP2 inhibited the proliferation, migration, and invasion of liver cancer cells. In vivo studies confirmed increased BMP2 expression in HCC tissues, promoting angiogenesis and HCC growth.
Conclusion:
This study highlights the role of BMP2 in tumor angiogenesis and HCC progression. Targeting BMP2 could be a promising therapeutic strategy against HCC.
Insights
Bone morphogenetic protein 2 (BMP2) promotes hepatocellular carcinoma (HCC) growth and spread by driving tumor angiogenesis. Inhibiting BMP2 may offer a new therapeutic strategy for liver cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide.
- Understanding the molecular mechanisms driving HCC progression is crucial for developing effective therapies.
- Bone morphogenetic protein 2 (BMP2) has been implicated in various cancers, but its specific role in HCC requires further elucidation.
Purpose of the Study:
- To investigate the role of BMP2 in hepatocellular carcinoma (HCC) growth and metastasis.
- To combine single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) to identify key molecular players in HCC.
Main Methods:
- Analysis of scRNA-seq data from the GEO database and bulk RNA-seq data from TCGA.
- Identification and functional enrichment analysis of differentially expressed endothelial cell marker genes.
- In vitro experiments using Huh-7 HCC cell line and in vivo HCC models with BMP2 knockdown.
Main Results:
- BMP2 was identified as a key marker gene in HCC endothelial cells, with elevated expression correlating with poor prognosis.
- Silencing BMP2 in vitro significantly inhibited HCC cell proliferation, migration, and invasion.
- In vivo studies demonstrated that increased BMP2 expression promotes angiogenesis and HCC growth.
Conclusions:
- BMP2 plays a critical role in promoting tumor angiogenesis and progression in HCC.
- Targeting BMP2 represents a potential therapeutic strategy for managing hepatocellular carcinoma.
More Related Videos
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
